Nature Reviews Cardiology最新文献_第4页

Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women 综合衡量炎症、胆固醇和脂蛋白（a）可预测女性 30 年的心血管风险

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-09-17 DOI: 10.1038/s41569-024-01082-2

Karina Huynh

引用次数: 0

Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD 克隆性造血：动脉粥样硬化性心血管疾病的新致病风险因素

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-09-17 DOI: 10.1038/s41569-024-01081-3

Jennifer Harman

引用次数: 0

The gut microbiota in thrombosis 血栓形成中的肠道微生物群

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-09-17 DOI: 10.1038/s41569-024-01070-6

My Phung Khuu, Nadja Paeslack, Olga Dremova, Corinne Benakis, Klytaimnistra Kiouptsi, Christoph Reinhardt

引用次数: 0

Interferon response at the border zone of the infarcted heart 梗死心脏边界区的干扰素反应

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-09-17 DOI: 10.1038/s41569-024-01078-y

Karina Huynh

引用次数: 0

Differential roles of eosinophils in cardiovascular disease 嗜酸性粒细胞在心血管疾病中的不同作用

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-09-16 DOI: 10.1038/s41569-024-01071-5

Junyan Xu, Junli Guo, Tianxiao Liu, Chongzhe Yang, Zhaojie Meng, Peter Libby, Jinying Zhang, Guo-Ping Shi

{"title":"Differential roles of eosinophils in cardiovascular disease","authors":"Junyan Xu, Junli Guo, Tianxiao Liu, Chongzhe Yang, Zhaojie Meng, Peter Libby, Jinying Zhang, Guo-Ping Shi","doi":"10.1038/s41569-024-01071-5","DOIUrl":"https://doi.org/10.1038/s41569-024-01071-5","url":null,"abstract":"Eosinophils are essential innate immune cells in allergic responses. Accumulating evidence indicates that eosinophils also participate in the pathogenesis of cardiovascular diseases (CVDs). In clinical studies, high blood eosinophil counts and eosinophil cationic protein levels have been associated with an increased risk of CVD, including myocardial infarction (MI), cardiac hypertrophy, atrial fibrillation, abdominal aortic aneurysm (AAA) and atherosclerosis. However, low blood eosinophil counts have also been reported to be a risk factor for MI, heart failure, aortic dissection, AAA, deep vein thrombosis, pulmonary embolism and ischaemic stroke. Although these conflicting clinical observations remain unexplained, CVD status, timing of eosinophil data collection, and tissue eosinophil phenotypic and functional heterogeneities might account for these discrepancies. Preclinical studies suggest that eosinophils have protective actions in MI, cardiac hypertrophy, heart failure and AAA. By contrast, cationic proteins and platelet-activating factor from eosinophils have been shown to promote vascular smooth muscle cell proliferation, vascular calcification, thrombomodulin inactivation and platelet activation and aggregation, thereby exacerbating atherosclerosis, atrial fibrillation, thrombosis and associated complications. Therefore, eosinophils seem to promote calcification and thrombosis in chronic CVD but are protective in acute cardiovascular settings. In this Review, we summarize the available clinical and preclinical data on the different roles of eosinophils in CVD.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"5 1","pages":""},"PeriodicalIF":49.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atheroimmunology: keeping the immune system in atherosclerosis in check 动脉粥样硬化免疫学：控制动脉粥样硬化的免疫系统

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-09-11 DOI: 10.1038/s41569-024-01075-1

Claudia Monaco, Lea Dib

引用次数: 0

Pathophysiological insights into HFpEF from studies of human cardiac tissue 从人体心脏组织研究中了解高频心衰的病理生理学原理

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-08-28 DOI: 10.1038/s41569-024-01067-1

Ahmed U. Fayyaz, Muhammad Eltony, Larry J. Prokop, Katlyn E. Koepp, Barry A. Borlaug, Surendra Dasari, Melanie C. Bois, Kenneth B. Margulies, Joesph J. Maleszewski, Ying Wang, Margaret M. Redfield

{"title":"Pathophysiological insights into HFpEF from studies of human cardiac tissue","authors":"Ahmed U. Fayyaz, Muhammad Eltony, Larry J. Prokop, Katlyn E. Koepp, Barry A. Borlaug, Surendra Dasari, Melanie C. Bois, Kenneth B. Margulies, Joesph J. Maleszewski, Ying Wang, Margaret M. Redfield","doi":"10.1038/s41569-024-01067-1","DOIUrl":"https://doi.org/10.1038/s41569-024-01067-1","url":null,"abstract":"Heart failure with preserved ejection fraction (HFpEF) is a major, worldwide health-care problem. Few therapies for HFpEF exist because the pathophysiology of this condition is poorly defined and, increasingly, postulated to be diverse. Although perturbations in other organs contribute to the clinical profile in HFpEF, altered cardiac structure, function or both are the primary causes of this heart failure syndrome. Therefore, studying myocardial tissue is fundamental to improve pathophysiological insights and therapeutic discovery in HFpEF. Most studies of myocardial changes in HFpEF have relied on cardiac tissue from animal models without (or with limited) confirmatory studies in human cardiac tissue. Animal models of HFpEF have evolved based on theoretical HFpEF aetiologies, but these models might not reflect the complex pathophysiology of human HFpEF. The focus of this Review is the pathophysiological insights gained from studies of human HFpEF myocardium. We outline the rationale for these studies, the challenges and opportunities in obtaining myocardial tissue from patients with HFpEF and relevant comparator groups, the analytical approaches, the pathophysiological insights gained to date and the remaining knowledge gaps. Our objective is to provide a roadmap for future studies of cardiac tissue from diverse cohorts of patients with HFpEF, coupling discovery biology with measures to account for pathophysiological diversity.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"22 1","pages":""},"PeriodicalIF":49.6,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142085620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms and treatment of pulmonary arterial hypertension 肺动脉高压的机制和治疗

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-08-07 DOI: 10.1038/s41569-024-01064-4

Hossein-Ardeschir Ghofrani, Mardi Gomberg-Maitland, Lan Zhao, Friedrich Grimminger

{"title":"Mechanisms and treatment of pulmonary arterial hypertension","authors":"Hossein-Ardeschir Ghofrani, Mardi Gomberg-Maitland, Lan Zhao, Friedrich Grimminger","doi":"10.1038/s41569-024-01064-4","DOIUrl":"https://doi.org/10.1038/s41569-024-01064-4","url":null,"abstract":"Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited to symptomatic relief by correcting the imbalance of vasoactive factors. The tyrosine kinase inhibitor imatinib, the first predominantly non-vasodilatory drug to be tested in patients with PAH, improved exercise capacity and pulmonary haemodynamics compared with placebo but at the expense of adverse events such as subdural haematoma. Given that administration by inhalation might reduce the risk of systemic adverse effects, inhaled formulations of tyrosine kinase inhibitors are currently in clinical development. Other novel therapeutic approaches for PAH include suppression of activin receptor type IIA signalling with sotatercept, which has shown substantial efficacy in clinical trials and was approved for use in the USA in 2024, but the long-term safety of the drug remains unclear. Future advances in the management of PAH will focus on right ventricular function and involve deep phenotyping and the development of a personalized medicine approach. In this Review, we summarize the mechanisms underlying PAH, provide an overview of available PAH therapies and their limitations, describe the development of newer, predominantly non-vasodilatory drugs that are currently being tested in phase II or III clinical trials, and discuss future directions for PAH research.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"367 1","pages":""},"PeriodicalIF":49.6,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141899446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stroke triggers an innate immune memory that drives cardiac dysfunction 中风引发先天性免疫记忆，导致心脏功能障碍

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-08-07 DOI: 10.1038/s41569-024-01069-z

Irene Fernández-Ruiz

引用次数: 0

Potential new therapeutic target for HFpEF 高频心衰的潜在新治疗靶点。

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-07-29 DOI: 10.1038/s41569-024-01066-2

Irene Fernández-Ruiz

引用次数: 0